PMC Articles for MedGen (Select 1702679) - PMC

Select item 104878161.

Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas

Andrea Estrella Arias-Diaz, Miriam Ferreiro-Pantin, Jorge Barbazan, Edurne Perez-Beliz, Juan Ruiz-Bañobre, Carlos Casas-Arozamena, Laura Muinelo-Romay, Rafael Lopez-Lopez, Ana Vilar, Teresa Curiel, Miguel Abal

Int J Mol Sci. 2023 Sep; 24(17): 13208. Published online 2023 Aug 25. doi: 10.3390/ijms241713208

PMCID:: PMC10487816

Article PDF–9.2M

Select item 104629992.

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report

Fiamma Buttitta, Pietro Di Marino, Lara Felicioni, Francesca Chiara Primavera, Benedetta Ferro, Claudia Zampacorta, Maria Paola Pasciuto, Rebecca Rossetti, Marianna Tudini, Antonio Marchetti, Emanuela D’Angelo

Pathologica. 2023 Apr; 115(2): 107–110. Published online 2023 Apr 30. doi: 10.32074/1591-951X-871

PMCID:: PMC10462999

Article PDF–164K

Select item 100208033.

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer

Richard T Penson, Allison J Ambrosio, Christin A Whalen, Carolyn N Krasner, Panagiotis A Konstantinopoulos, Charles Bradley, Ursula A Matulonis, Michael J Birrer

Oncologist. 2023 Mar; 28(3): 252–257. Published online 2023 Jan 30. doi: 10.1093/oncolo/oyac275

PMCID:: PMC10020803

Article PDF–436K

Select item 97689414.

Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations

Hongwen Yao, Ning Li, Hua Yuan

BMC Cancer. 2022; 22: 1337. Published online 2022 Dec 21. doi: 10.1186/s12885-022-10456-z

PMCID:: PMC9768941

Article PDF–775K

Select item 91068475.

Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity

Brian Orr, Haider Mahdi, Yusi Fang, Mary Strange, Ibrahim Uygun, Mainpal Rana, Lixin Zhang, Adria Suarez Mora, Alexandra Pusateri, Esther Elishaev, Chaeryon Kang, George Tseng, William Gooding, Robert P Edwards, Pawel Kalinski, Anda M Vlad

Clin Cancer Res. Author manuscript; available in PMC 2022 Nov 13.

Published in final edited form as: Clin Cancer Res. 2022 May 13; 28(10): 2038–2049. doi: 10.1158/1078-0432.CCR-21-3659

PMCID:: PMC9106847

Article PDF–1.7M

Select item 82401256.

Using PARP Inhibitors in the Treatment of Patients with Ovarian Cancer

Katherine Kurnit, Robert L. Coleman, Shannon N. Westin

Curr Treat Options Oncol. Author manuscript; available in PMC 2021 Jun 29.

Published in final edited form as: Curr Treat Options Oncol. 2018 Nov 15; 19(12): 1. Published online 2018 Nov 15. doi: 10.1007/s11864-018-0572-7

PMCID:: PMC8240125

Article PDF–84K

Select item 48447937.

Characteristics of 10-year survivors of high-grade serous ovarian carcinoma

Fanny Dao, Brooke A Schlappe, Jill Tseng, Jenny Lester, Alpa M. Nick, Susan K. Lutgendorf, Scott McMeekin, Robert L. Coleman, Kathleen N. Moore5, Beth Y. Karlan, Anil K. Sood, Douglas A Levine

Gynecol Oncol. Author manuscript; available in PMC 2017 May 1.

Published in final edited form as: Gynecol Oncol. 2016 May; 141(2): 260–263. Published online 2016 Mar 11. doi: 10.1016/j.ygyno.2016.03.010

PMCID:: PMC4844793

Article PDF–313K

Select item 44475258.

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG Oncology/Gynecologic Oncology Group study

Robert L. Coleman, Michael W. Sill, Katherine Bell-McGuinn, Carol Aghajanian, Heidi J. Gray, Krishnansu S. Tewari, Steven C. Rubin, Thomas J. Rutherford, John K Chan, Alice Chen, Elizabeth M. Swisher

Gynecol Oncol. Author manuscript; available in PMC 2016 Jun 1.

Published in final edited form as: Gynecol Oncol. 2015 Jun; 137(3): 386–391. Published online 2015 Mar 24. doi: 10.1016/j.ygyno.2015.03.042

PMCID:: PMC4447525

Article PDF–606K

Select item 31004129.

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies

Lydia Usha, Michael W. Sill, Kathleen M. Darcy, Doris M. Benbrook, Jean A Hurteau, David P. Michelin, Robert S. Mannel, Parviz Hanjani, Koen De Geest, Andrew K. Godwin

Gynecol Oncol. Author manuscript; available in PMC 2012 Jun 1.

Published in final edited form as: Gynecol Oncol. 2011 Jun 1; 121(3): 455–461. Published online 2011 Mar 17. doi: 10.1016/j.ygyno.2011.02.013

PMCID:: PMC3100412

Article PDF–396K

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to:

Links from MedGen

Items: 9

Display Settings:

Send to:

Supplemental Content

Find related data

Recent activity